CRISPR Therapeutics AG: Peers

The FY2023 (Dec) proxy of CRISPR Therapeutics AG names 19 peer companies for pay. Among CRISPR Therapeutics AG and these peers, CEO pay was 3rd highest of 6 and total shareholder return was 5th highest of 6.

3rd highest of 6in CRISPR Therapeutics AG and its pay peers, FY2023 (Dec) by CEO pay:

$6.3M$15.8M

5th highest of 6in CRISPR Therapeutics AG and its pay peers, FY2023 (Dec) by total shareholder return:

$84$166

Pay peer group, FY2023 (Dec) proxy

Neurocrine Biosciences
Ionis Pharmaceuticals
BridgeBio Pharma
Alnylam Pharmaceuticals
Beam Therapeutics
Allogene TherapeuticsNot disclosedNot disclosed
Apellis PharmaceuticalsNot disclosedNot disclosed
Arrowhead PharmaceuticalsNot disclosedNot disclosed
Blueprint MedicinesNot disclosedNot disclosed
Cerevel TherapeuticsNot disclosedNot disclosed
Denali TherapeuticsNot disclosedNot disclosed
Editas MedicineNot disclosedNot disclosed
Fate TherapeuticsNot disclosedNot disclosed
Intellia TherapeuticsNot disclosedNot disclosed
Iovance BioTherapeuticsNot disclosedNot disclosed
Mirati TherapeuticsNot disclosedNot disclosed
Sarepta TherapeuticsNot disclosedNot disclosed
Ultragenyx PharmaceuticsNot disclosedNot disclosed
Vir BiotechnologyNot disclosedNot disclosed
19 companies

Changes by year

No proxy on file names a change to the peer group.

The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year. Each company counts TSR from its own start year, so two values compare only when the start years match.